cas 830346-47-9, Benzeneacetic acid, 4-fluoro-.alpha.-(1-methylethyl)-, (.alpha.S)-

Articles about 830346-47-9Total 19 be found

Article title
Article abstract
Author
Journal number and time
Download

Preparation method of olagolide intermediate
The present invention relates to a method for preparing a lacolagoli intermediate 5-bromo-1- {[2-fluoro-6-(trifluoromethyl)phenyl] methyl}-6-methyl-2,4 (1H, 3H) pyrimidinedione (compound of formula I), in particular, a compound of formula III with 2-fluor
-
Paragraph 0036-0037; 0040-0041; 0044-0045; 0049-0050

(2022/01/12)

Preparation method of elagolix intermediate
The invention relates to a preparation method of an elagolix intermediate 1-(2-fluoro-6-trifluoromethylphenyl)-6-methyl pyrimidine-2,4(1H,3H)-diketone (I). The method comprises the following steps: taking 1-(2-fluoro-6-trifluoromethylphenyl)urea (V) and acetacetate (IV) protected by ketal as raw materials, reacting in the presence of alkali to obtain a ketal intermediate (III), and converting theketal intermediate (III) into N-((2-fluoro-6-trifluoromethylphenyl)carbamoyl)-3-oxobutylamide (II); and finally, carrying out a ring closing reaction to obtain the elagolix intermediate 1-(2-fluoro-6-trifluoromethylphenyl)-6-methyl pyrimidine-2,4(1H,3H)-diketone (I). According to the invention, the initial raw materials are cheap and easily available, and ketal-protected acetoacetate (IV) is usedas the raw material, so that the generation of isomers is avoided, and the product quality is improved.
-
(2021/01/25)

AN IMPROVED PROCESS FOR THE PREPARATION OF 4-({(1 R)-2-[5-(2-FLUORO-3METHOXYPHENYL)-3-{[2-FLUORO-6-(TRIFLUORO METHYL) PHENYL]METHYL}-4-METHYL-2,6-DIOXO-3,6DIHYDROPYRIMIDIN-1(2 H)-YL]-1-PHENYLETHYL}AMINO)BUTANOIC ACID OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS
The present invention relates to an improved process for the preparation of 4- ({(1R) -2- [5- (2-fluoro- 3- methoxy phenyl) – 3 - {[ 2-fluoro- 6-(trifluoro methyl) phenyl] methyl} -4-methyl- 2,6-dioxo- 3,6-dihydropyrimidin-1(2H)-yl]-1-phenylethyl}amino) butanoic acid of formula (I) or its pharmaceutically acceptable salts. The compound of formula (I) is represented by the following structural formula.
-
(2021/07/02)

METHOD FOR PREPARING ELAGOLIX INTERMEDIATE AND COMPOSITION THEREOF
The present invention relates to a method for preparing an intermediate (Formula IV) of sodium elagolix. The intermediate is prepared by the following route. The method has advantages of simple and safe operation, high yield, less environmental pollution, good economic effect and suitability for industrial production, wherein R represents C1-C4 substituted or unsubstituted benzyl or allyl.
-
(2020/12/08)

Elagolix intermediate preparation method
The invention discloses an elagolix intermediate preparation method, which specially comprises: 1, preparing 1-fluoro-2-(iodomethyl)-3-(trifluoromethyl)benzene from 2-trifluoromethyl-6-fluorobenzaldehyde, an iodinating reagent and a mixed solvent under th
-
(2020/01/25)

Substituted pyrimidine-2, 4(1H, 3H)-dione derivative and uses thereof
The invention belongs to the technical field of medicines, and relates to a substituted pyrimidine-2, 4(1H, 3H)-dione derivative and uses thereof, and a pharmaceutical composition containing the compound. The derivative and the pharmaceutical composition can be used as gonadotropin releasing hormone receptor antagonists. The invention also relates to a method for preparing the compound and the pharmaceutical composition, and uses of the compound and the pharmaceutical composition in prevention or treatment of sex hormone dependent diseases including but not limited to prostate cancer, endometriosis, hysteromyoma, precocious puberty and the like.
-
Paragraph 0138; 0143; 0148-0151

(2020/07/12)

Preparation method of compound containing 6-methyluracil structure
The invention discloses a preparation method of a compound containing a 6-methyluracil structure. The invention relates to the technical field of synthesis of medical intermediates and organic chemical intermediates. The method comprises the following synthesis steps of: (1) reacting ethyl carbamate serving as a compound 1 with ethyl acetoacetate serving as a compound 2 under a heating condition under the action of an organic solvent and a catalyst to generate a compound 3 that is oxazine diketone; and (2) reacting the compound 3 with a compound 4 that is 2-fluoro-6-(trifluoromethyl) phenyl) methylamine under the condition of heating, an organic solvent or no solvent to generate a compound 5, i.e., a 6-methyl-uracil substituted derivative. The method disclosed by the invention is suitablefor industrial production and relatively low in cost, and the prepared product is high in purity and yield.
-
Paragraph 0038; 0047-0052; 0054; 0058-0059; 0060; 0064-0065

(2020/07/12)

Preparation method of elagolix intermediate
The invention relates to a preparation method of an elagolix intermediate (IV). The method is carried out according to the following route, and the synthetic route is short. The method has the advantages of simple and safe operation, good yield, small env
-
Paragraph 0026-0053; 0062-0071

(2019/10/02)

Method for synthesizing Elagolix midbody polysubstituted pyrimidine derivate through two-step method
The invention discloses a method for synthesizing an Elagolix midbody polysubstituted pyrimidine derivate through a two-step method. The method comprises the following steps that (1) (2-fluoro-6-(trifluoromethyl)phenyl)methylamine shown as a formula II re
-
Page/Page column 6-10

(2019/06/11)

PROCESSES TO PRODUCE ELAGOLIX
The present invention relates to a scalable process for the making of elagolix, its salts and the process of intermediate compounds.
-
Page/Page column 13; 14

(2019/06/23)

Preparation method of multi-substituted pyridine derivative used as Elagolix intermediate
The invention discloses a preparation method of a multi-substituted pyridine derivative used as an Elagolix intermediate. The preparation method is characterized by carrying out alkylation reaction on2-(bromomethyl)-1-fluoro-3-(trifluoromethyl)benzene as
-
Paragraph 0024-0037

(2019/06/05)

PROCESS FOR THE PREPARATION OF ELAGOLIX AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
The present invention relates to a process for the preparation of Elagolix of formula (I) and its pharmaceutically acceptable salts. The present invention also relates to an intermediate of formula (VIII) and its use in preparation of Elagolix and its pharmaceutically acceptable salts.
-
Page/Page column 12; 13

(2018/11/22)

PROCESSES FOR THE PREPARATION OF URACIL DERIVATIVES
The present invention relates to processes and intermediates for preparing Gonadotropin-Releasing Hormone (GnRH) receptor antagonists of structure (VI); and stereoisomers and pharmaceutically acceptable salts thereof.
-
Page/Page column 8

(2009/06/27)

Discovery of sodium R-(+)-4-{2-[5-(2-Fluoro-3-methoxyphenyl)-3-(2-fluoro-6- [trifluoromethyl]-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl] -1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor
The discovery of novel uracil phenylethylamines bearing a butyric acid as potent human gonadotropin-releasing hormone receptor (hGnRH-R) antagonists is described. A major focus of this optimization was to improve the CYP3A4 inhibition liability of these uracils while maintaining their GnRH-R potency. R-4-{2-[5-(2-Fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl) -4-methyl-2,6-dioxo-3,6-dihy-dro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyric acid sodium salt, 10b (elagolix), was identified as a potent and selective hGnRH-R antagonist. Oral administration of 10b suppressed luteinizing hormone in castrated macaques. These efforts led to the identification of 10b as a clinical compound for the treatment of endometriosis.
Chen, Chen,Wu, Dongpei,Guo, Zhiqiang,Xie, Qiu,Reinhart, Greg J.,Madan, Ajay,Wen, Jenny,Chen, Takung,Huang, Charles Q.,Chen, Mi,Chen, Yongsheng,Tucci, Fabio C.,Rowbottom, Martin,Pontillo, Joseph,Zhu, Yun-Fei,Wade, Warren,Saunders, John,Bozigian, Haig,Struthers, R. Scott
experimental part
p. 7478 - 7485
(2009/12/07)

5-Aryluracils as potent GnRH antagonists-Characterization of atropisomers
Optimization of a series of uracils bearing a 2-fluoro- or 2-chloro-3-methoxyphenyl group at the 5-position resulted in compounds such as 3d and 3f with subnanomolar binding affinity at the human GnRH receptor. While the 2-fluoro-3-methoxyphenyl compound 3a was characterized as a mixture of interchangeable atropisomers, the diastereoisomers of 2-chloro-3-methoxyphenyl analogs were separated. It was found that the aR-atropisomer was much more potent than the aS-isomer based on the X-ray crystal structure of 3h-II.
Zhao, Liren,Guo, Zhiqiang,Chen, Yongsheng,Hu, Tao,Wu, Dongpei,Zhu, Yun-Fei,Rowbottom, Martin,Gross, Timothy D.,Tucci, Fabio C.,Struthers, R. Scott,Xie, Qiu,Chen, Chen
scheme or table
p. 3344 - 3349
(2009/04/11)

URACIL-TYPE GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATED THERETO
Compounds having utility as GnRH receptor antagonists and for treatment of a variety of sex-hormone related conditions in both men and women. Such compounds have the following structure (I): (I) wherein R1a, R1b, R1c, R2a, R2b, R3, R4, R5, R6, R7, n and X are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of structure (I) in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.
-
Page/Page column 21-22

(2010/02/14)

PYRIMIDINE-2,4-DIONE DERIVATIVES AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS
GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure formula (I) wherein R1a, R1b, R2a, R2b, R3, R4, R5, R6, R7 and X are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.
-
Page 26

(2008/06/13)

PYRIMIDINE-2, 4-DIONE DERIVATIVES AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS
GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R1a, R1b, R1c, R2a, R2b, R3, R4, R5, R6 and X are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.
-
Page 27

(2010/02/10)

GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO
GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein n, R1a, R1b, R1c, R2a, R2b, R3, R4, R5, R6 and X are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.
-
Page 38

(2010/02/10)